NASDAQ: LABTRank 05 / 10Clinical-stage antimicrobials
Lakewood-Amedex Biotherapeutics Inc.
Clinical-stage biotech developing Bisphosphocins, a novel class of fast-acting, broad-spectrum antimicrobials targeting resistant strains such as MRSA and VRE.
lakewoodamedex.com ↗0.1950USD+5.41%
Market cap$462.1K
Shares (impl.)2,369,687
52W high98.20
52W low0.1687
From high-99.80%
Volume880,851
Why it is on the list
Antibiotic resistance is a real problem with a real pipeline attached. Clinical-stage biotech is binary — which is exactly why it trades this cheap.
Principal risk
Binary clinical outcomes; financing needs ahead of every trial readout.
A
Ownership ladder
Costs at last print, before price impact
Routed to LABT
…
—
Fundable stake
0%
of shares outstanding
Paired tokens
…
1%
5%
10%
50.1%
0.001%0.01%0.1%1%10%100%
Share of company fundable by routed fees · log scale
| Stake | Meaning | Cost | To go |
|---|---|---|---|
| 1% | Top-holder list on most micro-caps | $4.6K | $4.6K |
| 5% | Schedule 13D/13G beneficial-owner filing | $23.1K | $23.1K |
| 10% | Section 16 insider status | $46.2K | $46.2K |
| 50.1% | Majority control of the vote | $231.5K | $231.5K |
Reading pools…